Caution with concomitant Zelboraf and radiation treatment
The summary of product characteristics for Zelboraf (vemurafenib; Roche) now states that cases of radiation recall and radiation sensitisation have been reported in patients treated with radiation either prior, during, or subsequent to vemurafenib treatment. Therefore, vemurafenib should be used with caution when given concomitantly or sequentially with radiation treatment.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20200189
Recommended from Pharmaceutical Press